Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Enable Injections has developed the enFuse platform—a purely mechanical, hands-free wearable device that delivers large volumes of drugs subcutaneously. The company’s technology enables patients to self-administer medications at home instead of receiving intravenous infusions at clinics. The first commercial product using enFuse was approved by the FDA in combination with a partner’s therapy. Recent milestones include CE Mark approval in Europe and positive Phase III results for Sarclisa delivered via enFuse. The company has expanded partnerships with major pharma companies such as Roche to develop further combination products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Enable Injections.